AMYVID Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Amyvid patents expire, and what generic alternatives are available?
Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.
This drug has forty-nine patent family members in thirty-two countries.
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Amyvid
Amyvid was eligible for patent challenges on April 6, 2016.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 30, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for AMYVID
International Patents: | 49 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 8 |
Clinical Trials: | 39 |
Patent Applications: | 264 |
What excipients (inactive ingredients) are in AMYVID? | AMYVID excipients list |
DailyMed Link: | AMYVID at DailyMed |

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AMYVID
Generic Entry Date for AMYVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for AMYVID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Puerto Rico | Phase 2 |
Universidad Central del Caribe | Phase 2 |
Invicro | Phase 1 |
Pharmacology for AMYVID
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for AMYVID
AMYVID is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AMYVID is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting AMYVID
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-002 | Apr 6, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-002 | Apr 6, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-003 | Apr 6, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-003 | Apr 6, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AMYVID
When does loss-of-exclusivity occur for AMYVID?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07243712
Estimated Expiration: ⤷ Try a Trial
Austria
Patent: 9060
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0710225
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 44530
Estimated Expiration: ⤷ Try a Trial
China
Patent: 1522624
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 329
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0120135
Estimated Expiration: ⤷ Try a Trial
Patent: 0170857
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 13048
Estimated Expiration: ⤷ Try a Trial
Patent: 19048
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 99109
Estimated Expiration: ⤷ Try a Trial
Patent: 63392
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 088783
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 7898
Estimated Expiration: ⤷ Try a Trial
Patent: 0870389
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 99109
Estimated Expiration: ⤷ Try a Trial
Patent: 63391
Estimated Expiration: ⤷ Try a Trial
Patent: 63392
Estimated Expiration: ⤷ Try a Trial
Guatemala
Patent: 0800201
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 32660
Estimated Expiration: ⤷ Try a Trial
Patent: 300028
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 3567
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 90954
Estimated Expiration: ⤷ Try a Trial
Patent: 09532349
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 63392
Estimated Expiration: ⤷ Try a Trial
Luxembourg
Patent: 232
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 08012527
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 0887
Estimated Expiration: ⤷ Try a Trial
Norway
Patent: 2090
Estimated Expiration: ⤷ Try a Trial
Patent: 18030
Estimated Expiration: ⤷ Try a Trial
Patent: 084590
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 99109
Estimated Expiration: ⤷ Try a Trial
Patent: 63392
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 99109
Estimated Expiration: ⤷ Try a Trial
Patent: 63392
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 222
Estimated Expiration: ⤷ Try a Trial
Patent: 171
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 3338
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 99109
Estimated Expiration: ⤷ Try a Trial
Patent: 63392
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 0807955
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1376807
Estimated Expiration: ⤷ Try a Trial
Patent: 080106564
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 78785
Estimated Expiration: ⤷ Try a Trial
Patent: 28882
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 99366
Estimated Expiration: ⤷ Try a Trial
Patent: 0838852
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 802
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering AMYVID around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 2008012527 | DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNION A PLACAS AMILOIDES Y OBTENCION DE IMAGENES DE LAS MISMAS. (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES.) | ⤷ Try a Trial |
Singapore | 173338 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | ⤷ Try a Trial |
Denmark | 1999109 | ⤷ Try a Trial | |
Poland | 2363392 | ⤷ Try a Trial | |
Hungary | E032660 | ⤷ Try a Trial | |
European Patent Office | 1999109 | DÉRIVÉS DE STYRYLPYRIDINE ET LEURS APPLICATIONS À LA LIAISON ET À L'IMAGERIE DE PLAQUES AMYLOÏDES (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AMYVID
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1999109 | 481 | Finland | ⤷ Try a Trial | |
1999109 | C20130016 00076 | Estonia | ⤷ Try a Trial | PRODUCT NAME: FLORBETAPIIR (18F);REG NO/DATE: K(2013)137 (LOPLIK) 14.01.2013 |
1999109 | PA2013016 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114 |
1999109 | C01999109/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: SWISSMEDIC 62897 09.01.2014 |
1999109 | 1390030-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: FLORBETAPIR (18F); REG. NO/DATE: EU/1/12/805 20130114 |
1999109 | SPC/GB13/040 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FLORBETAPIR (18F) ((E)-4-(2-(6-(2-(2-(2-((18F)-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL(18F); REGISTERED: UK EU/1/12/805 20130117 )VINYL)-N-METHYL BENZENAMINE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY FLORBETAPIR |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |